Research Topics
| T ConroySummaryAffiliation: Institut Paoli-Calmettes Country: France Publications
| Collaborators
|
Detail Information
Publications
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer studyThierry Conroy
Department of Medical Oncology, Centre Alexis Vautrin, 54511 Vandoeuvre les Nancy Cedex, France
J Clin Oncol 23:1228-36. 2005..To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA)...
Activity of vinorelbine in gastrointestinal cancersThierry Conroy
Department of Medical Oncology, Centre Alexis Vautrin, 6 avenue de Bourgogne, 54511 Vandoeuvre les Nancy Cedex, France
Crit Rev Oncol Hematol 42:173-8. 2002..The response rate was 37% (95% CI, 26-49%) with a median duration of response of 7.7 months. This 2-day regimen appears at least as active and less toxic than the standard 5-day 5-FU and cisplatin regimen...
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerThierry Conroy
Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
N Engl J Med 364:1817-25. 2011....
Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patientsJohannes M Giesinger
Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria
Health Qual Life Outcomes 9:19. 2011..These new CAT measures are conceptualised to reflect the same constructs as the QLQ-C30 scales. Accordingly, the Fatigue-CAT is intended to capture physical and general fatigue...
Quality of life in patients with advanced colorectal cancer: what has been learnt?T Conroy
Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
Eur J Cancer 39:287-94. 2003..An international consensus on the methods of measurement of HRQoL in oncology is warranted to enhance compliance, to better interpret results and to optimise the publication of precise HRQoL data...
Health-related quality of life in colorectal cancer patientsThierry Conroy
Medical Oncology Department and EA 3444, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
Expert Rev Anticancer Ther 3:493-504. 2003..An international consensus involving clinicians and methodologists is needed to describe robust standards for quality of life measurement in oncology...
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancerT Conroy
Centre Alexis Vautrin, Department of Medical Oncology, Nancy University, 6 avenue de Bourgogne, 54511 Vandœuvre lès Nancy Cedex 54511, France
Br J Cancer 103:1349-55. 2010..A randomised phase II trial was initiated to assess the feasibility and efficacy in terms of the endoscopic complete response rate (ECRR) of radiotherapy with oxaliplatin, leucovorin and fluorouracil (FOLFOX4) or cisplatin/fluorouracil...
French version of FACT-G: validation and comparison with other cancer-specific instrumentsT Conroy
Department of Medical Oncology, Centre Alexis Vautrin, 54500 Vandoeuvre les Nancy, France
Eur J Cancer 40:2243-52. 2004..Use of the specific H&N additional items increased the responsiveness to change of FACT-G. The French version of FACT-G is valid and has psychometric properties similar to those of FLIC and QLQ-C30...
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerT Conroy
Centre Alexis Vautrin and Nancy University, EA 4360, Vandoeuvre lès Nancy 54511, France
Br J Cancer 102:59-67. 2010..A secondary objective was to compare the quality of life (QoL) and health-care satisfaction of patients...
Health-related quality-of-life assessment in gastrointestinal cancer: are results relevant for clinical practice?Thierry Conroy
Department of Medical Oncology, Alexis Vautrin Centre and EA 4003, Nancy University, Vandoeuvre les Nancy, France
Curr Opin Oncol 19:401-6. 2007..We review recent literature to evaluate whether quality-of-life assessment contributes to optimal patient information and helps treatment choices...
Quality of life in patients with oesophageal and gastric cancer: an overviewThierry Conroy
Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
Oncology 70:391-402. 2006..This article reviews the impact of surgery and reconstructive techniques, as well as of adjuvant and palliative treatments on the QoL of patients with OGC...
Metastatic pancreatic cancer: old drugs, new paradigmsThierry Conroy
Department of Medical Oncology, Centre Alexis Vautrin, Nancy University, Vandoeuvre les Nancy, France
Curr Opin Oncol 23:390-5. 2011..In this article, we will review current first-line treatments for metastatic pancreatic adenocarcinoma focusing on randomized studies...
[Measure of quality of life in patients with metastatic colorectal cancer: techniques and main results]T Conroy
Departement d Oncologie Medicale, Centre Alexis Vautrin, UPRES EA 1124 Epidémiologie clinique, prévention et qualité de vie Ecole de santé publique, Faculte de Medecine, Vandoeuvre les Nancy, France
Rev Med Interne 23:703-16. 2002..An international consensus on methods of measurement of quality of life in oncology is warranted to enhance compliance, to better interpret quality of life results et to optimize publications of precise quality of life data...
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survivalT Conroy
Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
Ann Oncol 13:721-9. 2002....
High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II studyD Peiffert
Centre Alexis Vautrin, Nancy, France
Ann Oncol 12:397-404. 2001..To analyse toxicity and response to a new scheme of neoadjuvant chemotherapy (CT) and concomitant radiochemotherapy (RT-CT) for locally advanced anal canal squamous-cell carcinoma (ACC)...
Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancerM C Kaminsky-Forrett
Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
Int J Radiat Oncol Biol Phys 42:935-41. 1998..To evaluate the prognostic value of tumor downstaging after preoperative radiation for resectable rectal cancer...
Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancerT Conroy
1Department of Medical Oncology and Radiotherapy, EA 4003, Nancy University and Centre Alexis Vautrin, 6 avenue de Bourgogne, 54511 Vandoeuvre les Nancy, France
Br J Cancer 99:1395-401. 2008..5%, including 12% complete response. Response rate on primary tumour was 62.9%. This FOLFOX-4 regimen was reasonably well tolerated and effective in inoperable/metastatic oesophageal carcinoma and warrants additional investigation...
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumabD Malka
Gastrointestinal Oncology Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
Ann Oncol 23:919-27. 2012..We investigated whether circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) patients...
Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-CChristine Rotonda
Nancy University, EA 4003, 54000 Vandoeuvre les Nancy, France
Qual Life Res 17:437-45. 2008....
Factors affecting local control and survival after treatment of carcinoma of the rectum by endocavitary radiation: a retrospective study of 97 casesP Rauch
Department of Surgery, Centre Alexis Vautrin, Vandoeuvre, France
Int J Radiat Oncol Biol Phys 49:117-24. 2001..We studied the prognostic factors for locoregional or metastatic relapse after endocavitary radiation, and their impact for therapeutic strategy...
Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: the FATSEIN studyC Rotonda
INSERM, CIC EC CIE6, Nancy, France
Contemp Clin Trials 32:244-9. 2011..Fatigue is now considered as the most distressing side effect of treatment. Fifty-eight percent to 94% of breast cancer patients experience fatigue during treatment with adjuvant chemotherapy...
A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectableF Bonnetain
Fédération Francophone de Cancérologie Digestive, Faculty of Medicine, 7 Boulevard Jeanne d Arc, 21079 Dijon Cedex, France
Ann Oncol 17:827-34. 2006..The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up...
High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective seriesJ Y Blay
Centre Leon Berard, Lyon, France
J Clin Oncol 16:864-71. 1998..The impact of treatment options on survival and late neurologic toxicity was investigated in a series of patients with primary cerebral lymphoma (PCL) and no known cause of immunosuppression...
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomasR Fety
Centre Rene Gauducheau, Nantes, France
Clin Cancer Res 4:2039-45. 1998..7% in the PK-arm. The present study is the first to demonstrate, in a randomized design, the clinical interest of an individual 5FU dose adaptation based on pharmacokinetic survey, in terms of therapeutic index improvement...
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumorsM Ychou
Centre Val d Aurelle, Montpellier, France
Ann Oncol 14:481-9. 2003..The aim of this study was to determine the maximum-tolerated dose (MTD) and the recommended dose of irinotecan and oxaliplatin with a fixed 5-fluorouracil (5-FU)/leucovorin (LV) regimen in patients with metastatic solid tumors...
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6G Perrocheau
Centre Rene Gauducheau, centre d investigation clinique, Saint Herblain, France
Oncology 79:174-80. 2010..The objective of this additional analysis was to compare the cost of XELOX and FOLFOX-6...
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou
Centre de Recherche et de Lutte contre le Cancer Val d Aurelle, Montpellier, France
Ann Oncol 20:674-80. 2009..This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse...
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trialMarc Ychou
Centre Regional de Lutte contre le Cancer Val d Aurelle, 298 rue des apothicaires 34298 Montpellier Cedex 05, France
J Clin Oncol 29:1715-21. 2011..This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma...
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203Jean Pierre Gerard
Centre Antoine Lacassagne, Radiotherapy Department, Nice, France
J Clin Oncol 24:4620-5. 2006..In 1992, preoperative radiotherapy was considered in France as the standard treatment for T3-4 rectal cancers. The present randomized trial compares preoperative radiotherapy with chemoradiotherapy...
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2Jean Pierre Gerard
Centre Antoine Lacassagne, 06189 Nice Cedex 2, France
J Clin Oncol 28:1638-44. 2010..Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecitabine and oxaliplatin...
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]Thierry Conroy
Centre Alexis Vautrin, Nancy
Bull Cancer 91:759-68. 2004..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
Quality of life among disease-free survivors of rectal cancerPhilippe Rauch
Surgical Department and Medical Oncology, Centre Alexis Vautrin, 54511 Vandoeuvre les Nancy, France
J Clin Oncol 22:354-60. 2004..To identify factors affecting the quality of life (QoL) of disease-free survivors of rectal cancer...
Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I studyEric Francois
Department of Medical Oncology, Centre Antoine Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France
Eur J Cancer 41:2861-7. 2005..The good safety profile of the regimen, associated with promising results in terms of histological response, suggest that the regimen could be developed in future phase II/III studies...
[Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review]Célia Roemer-Becuwe
Departement d Oncologie Medicale, Centre Alexis Vautrin, 54511 Vandoeuvre les Nancy
Bull Cancer 90:1097-105. 2003..Because of a lack of systemic data, reliable analysis of the results is difficult. Several questions remain open about which bisphosphonates and route of administration to choose, and the variable effects on different primaries...
[Quality of life measurement in cancer survivors]Simon Schraub
Centre de Lutte Contre le Cancer Paul Strauss, 3, rue de la Porte de l Hôpital, 67085 Strasbourg Cedex, France
Bull Cancer 89:267-74. 2002..QOL can be evaluated in a cohort of patients in a longitudinally study or better in a case control study. Examples of QOL evaluation of different cancers sites are given...
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncologyFranck Bonnetain
INSERM EMI 106 and Federation Francophone de Cancerologie Digestive, Faculty of Medicine, 7 bd Jeanne d Arc, BP 879000, 21079 Dijon Cedex
Gastroenterol Clin Biol 29:1113-24. 2005..The aim of this study was to compare the longitudinal quality of life (QoL) between LV5FU2-irinotecan and LV5FU2 alone or LV5FU2-cisplatin in a randomized Phase II trial in patients with metastatic gastric adenocarcinoma...
Late cardiopulmonary toxicity after treatment for Hodgkin's diseaseC Allavena
Centre Alexis Vautrin, Department of Radiotherapy, , France
Br J Cancer 65:908-12. 1992..We conclude that the treatment with mantle field under good technical conditions (high energy photons, moderate doses...) can result in minimal cardiopulmonary dysfunction...
[Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectal cancer]T Conroy
Centre Alexis Vautrin, Nancy
Bull Cancer 93:197-200. 2006
Quality of life in long-term survivors of oropharynx carcinomaNicolas Pourel
Department of Radiation Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
Int J Radiat Oncol Biol Phys 54:742-51. 2002..To collect data on the health-related quality of life (QOL) of long-term survivors and to determine to what extent QOL might be an appropriate end point in the comparison of treatment options in oropharyngeal carcinoma...
[Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]L Tournier-Rangeard
Département de radiothérapie et curiethérapie, Centre Alexis Vautrin, Avenue de Bourgogne, 54511 Vandoeuvre les Nancy Cedex, France
Cancer Radiother 11:169-77. 2007..To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution...
Surgical resection with and without chemotherapy in oesophageal cancerJean Francois Bosset
Lancet 360:1173-4; author reply 1175. 2002
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?Fabio Efficace
European Organisation for Research and Treatment of Cancer EORTC, EORTC Data Center, Quality of Life Unit, Avenue E Mounier 83, 1200 Brussels, Belgium
Eur J Cancer 42:42-9. 2006..The results suggest that social functioning, acts as a prognostic measure of survival beyond a number of previously known biomedical parameters...
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJim Cassidy
CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, Glasgow G61 1DB, United Kingdom
J Clin Oncol 22:2084-91. 2004..The present studies further characterize efficacy and safety of the XELOX regimen...
[Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)]Marc Ychou
Centre Val d'Aurelle, Montpellier
Bull Cancer 92:381-409. 2005....
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trialBernard Nordlinger
Hospital Ambroise Pare, Assistance Publique Hopitaux de Paris, 9 avenue Charles de Gaulle, Boulogne Billancourt Cedex 92104, France
Lancet Oncol 6:459-68. 2005..The study also compared systemic chemotherapy with fluorouracil and folinic acid with that of fluorouracil and levamisole...
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II studyChris J Twelves
University of Leeds and Bradford NHS Hospitals Trust, United Kingdom
Clin Colorectal Cancer 5:101-7. 2005..Capecitabine/oxaliplatin (XelOx) is a safe and active combination for the first-line treatment of metastatic CRC...
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomachPernilla Lagergren
Department of Social Medicine at South Bristol, University of Bristol, Bristol, United Kingdom
Eur J Cancer 43:2066-73. 2007..To combine and test the EORTC questionnaires for assessing quality of life (HRQL) for oesophageal (QLQ-OES18) and stomach cancer (QLQ-STO22), into a single questionnaire for tumours of the oesophagus, oesophago-gastric junction or stomach...
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102Laurent Bedenne
University Hospital Le Bocage, Dijon, France
J Clin Oncol 25:1160-8. 2007..Therefore, a randomized trial was carried out to compare, in responders only, chemoradiation alone with chemoradiation followed by surgery in patients with locally advanced tumors...
Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancerCatherine Lejeune
INSERM EMI (Equipe Mixte INSERM) 0106, Dijon, France
J Nucl Med 46:2020-8. 2005..However cost savings associated with its use and the improvement of therapeutic management therefore justify its generalization in clinical practice...
Metastatic colorectal cancerOlivier Bouche
, CHU Robert Debr, Reims
Gastroenterol Clin Biol 30:2S30-2S42. 2006
Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancerMohamed Hebbar
Medical Oncology Unit, University Hospital, Lille, France
Oncology 73:185-91. 2007..To identify easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer...
Use of differential item functioning analysis to assess the equivalence of translations of a questionnaireMorten Aa Petersen
Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark
Qual Life Res 12:373-85. 2003..We conclude that testing for DIF is a useful way to validate questionnaire translations...
